# Pharmacoeconomic Consequences Of Analgesia in the Intensive Care Unit (ICU)

> **NCT00436345** · PHASE3 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 39 (actual)

## Conditions studied

- Analgesia

## Interventions

- **DRUG:** Remifentanil
- **DRUG:** Propofol

## Key facts

- **NCT ID:** NCT00436345
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-11
- **Primary completion:** 2008-08
- **Final completion:** 2008-09
- **Target enrollment:** 39 (ACTUAL)
- **Why stopped:** recruitment issues
- **Last updated:** 2017-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00436345

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00436345, "Pharmacoeconomic Consequences Of Analgesia in the Intensive Care Unit (ICU)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00436345. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*